Ozempic under scrutiny for potential connection to suicidal ideation.

European Drug Safety Regulators Investigate Link Between Ozempic and Suicidal Thoughts

The European Medicines Agency’s drug safety panel is currently investigating whether popular diabetes and weight loss medications, including Ozempic, may be associated with an increase in suicidal thoughts among patients. This investigation comes after reports of two patients experiencing suicidal and self-harm thoughts while taking Ozempic, as well as one patient on a similar product called Saxenda, both of which are produced by Novo Nordisk, a Danish pharmaceutical company.

Concerns Surrounding GLP-1 Drugs

Ozempic, approved by the Food and Drug Administration for treating insulin-dependent Type II diabetes, is also used off-label as a weight loss medication. It contains the chemical semaglutide, which mimics the GLP-1 hormone responsible for promoting insulin development. The drug safety panel is now considering expanding the inquiry to include all GLP-1 drugs, such as Ozempic, Wegovy, and Saxenda, among others.

Challenges Faced by Patients

Patients prescribed Ozempic or Wegovy for diabetes or weight loss often struggle with consistency in taking their medication. This is partly because GLP-1 drugs function as appetite suppressants, leading to successful health effects but also causing a loss of pleasure sensation in eating. Jens Juul Hols, a scientist involved in the development of GLP-1 drugs, described the long-term experience as “miserably boring” in an interview with Wired.

Novo Nordisk’s Commitment to Patient Safety

Novo Nordisk, the manufacturer of these medications, emphasizes that patient safety is their top priority. They take all reports of adverse effects seriously and are closely monitoring the situation. In fact, GLP-1 drugs accounted for 57% of Novo Nordisk’s sales in 2022.

While thoughts of self-harm are not listed as a side effect of Ozempic, they are mentioned for Wegovy due to the results of a clinical trial involving other weight loss drugs. The FDA, as a policy, does not comment on investigations conducted by foreign drug regulatory bodies.

Click here to read more from The Washington Examiner.

*As an Amazon Associate I earn from qualifying purchases